Clinical publications

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

22 February, 2024 |

Categorized Clinical publications, Eblasakimab

Eblasakimab Improves Multiple Disease Measures in Adult Patients with Moderate-to-severe Atopic Dermatitis in a Randomized, Double-blinded, Placebo-controlled, Phase 1 Study

27 October, 2023 |

Categorized Clinical publications, Eblasakimab

Topline results from TREK-AD: a randomized, double-blind, placebo-controlled, Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis

27 October, 2023 |

For further details on the presentation, please refer to our press release.

Categorized Clinical publications, Eblasakimab

Eblasakimab Improves Itch and Sleep Loss in Adult Patients with Moderate-to-severe Atopic Dermatitis in a Randomized, Double-blinded, Placebo-controlled, Phase 1 Study

29 August, 2023 |

Categorized Clinical publications, Eblasakimab

Eblasakimab, a Monoclonal Antibody Targeting IL‑13Rα1 Reduces Serum Biomarkers Associated with Atopy and Correlated with Disease Severity in Patients With Moderate‑to‑Severe Atopic Dermatitis

29 August, 2023 |

Categorized Clinical publications, Eblasakimab

Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers

19 June, 2023 |

Categorized Clinical publications, Eblasakimab

Eblasakimab monotherapy improves moderate-to-severe atopic dermatitis symptoms across anatomical regions in a Phase 1 study

17 May, 2023 |

Categorized Clinical publications, Eblasakimab

Eblasakimab, a monoclonal antibody targeting IL-13Ra1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis

18 April, 2023 |

Categorized Clinical publications, Eblasakimab

Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study

18 April, 2023 |

Categorized Clinical publications, Eblasakimab

Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study

18 April, 2023 |

Categorized Clinical publications, Eblasakimab

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Eblasakimab Improves Multiple Disease Measures in Adult Patients with Moderate-to-severe Atopic Dermatitis in a Randomized, Double-blinded, Placebo-controlled, Phase 1 Study

Topline results from TREK-AD: a randomized, double-blind, placebo-controlled, Phase 2b study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis

Eblasakimab Improves Itch and Sleep Loss in Adult Patients with Moderate-to-severe Atopic Dermatitis in a Randomized, Double-blinded, Placebo-controlled, Phase 1 Study

Eblasakimab, a Monoclonal Antibody Targeting IL‑13Rα1 Reduces Serum Biomarkers Associated with Atopy and Correlated with Disease Severity in Patients With Moderate‑to‑Severe Atopic Dermatitis

Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers

Eblasakimab monotherapy improves moderate-to-severe atopic dermatitis symptoms across anatomical regions in a Phase 1 study

Eblasakimab, a monoclonal antibody targeting IL-13Ra1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis

Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study

Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study

Company

Contact Us

US Office

Singapore Office

Social Media